Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone

Results from two placebo-controlled bipolar i maintenance studies

Mark A Frye, L. Yatham, T. A. Ketter, J. Goldberg, T. Suppes, J. R. Calabrese, C. L. Bowden, E. Bourne, R. S. Bahn, B. Adams

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: To assess the relationship between depressive relapse and change in thyroid function in an exploratory post hoc analysis from a controlled maintenance evaluation of bipolar I disorder. Method: Mean thyroid-stimulating hormone (TSH) and outcome data were pooled from two 18-month, double-blind, placebo-controlled, maintenance studies of lamotrigine and lithium monotherapy. A post hoc analysis of 109 subjects (n = 55 lamotrigine, n = 32 lithium, n = 22 placebo) with serum TSH values at screening and either week 52 (±14 days) or study drop-out was conducted. Results: Lithium-treated subjects who required an intervention for a depressive episode had a significantly higher adjusted mean TSH level (4.4 μIU/ml) compared with lithium-treated subjects who did not require intervention for a depressive episode (2.4 μIU/ml). Conclusion: Lithium-related changes in thyroid function are clinically relevant and should be carefully monitored in the maintenance phase of bipolar disorder to maximize mood stability and minimize the risk of subsyndromal or syndromal depressive relapse.

Original languageEnglish (US)
Pages (from-to)10-13
Number of pages4
JournalActa Psychiatrica Scandinavica
Volume120
Issue number1
DOIs
StatePublished - Jul 2009

Fingerprint

Thyrotropin
Lithium
Placebos
Maintenance
Recurrence
Serum
Bipolar Disorder
Thyroid Gland
Therapeutics
lamotrigine

Keywords

  • Bipolar
  • Depression
  • Lithium
  • Thyroid-stimulating hormone

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone : Results from two placebo-controlled bipolar i maintenance studies. / Frye, Mark A; Yatham, L.; Ketter, T. A.; Goldberg, J.; Suppes, T.; Calabrese, J. R.; Bowden, C. L.; Bourne, E.; Bahn, R. S.; Adams, B.

In: Acta Psychiatrica Scandinavica, Vol. 120, No. 1, 07.2009, p. 10-13.

Research output: Contribution to journalArticle

Frye, Mark A ; Yatham, L. ; Ketter, T. A. ; Goldberg, J. ; Suppes, T. ; Calabrese, J. R. ; Bowden, C. L. ; Bourne, E. ; Bahn, R. S. ; Adams, B. / Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone : Results from two placebo-controlled bipolar i maintenance studies. In: Acta Psychiatrica Scandinavica. 2009 ; Vol. 120, No. 1. pp. 10-13.
@article{3f615d6631ff4d65982d1322aa26823d,
title = "Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: Results from two placebo-controlled bipolar i maintenance studies",
abstract = "Objective: To assess the relationship between depressive relapse and change in thyroid function in an exploratory post hoc analysis from a controlled maintenance evaluation of bipolar I disorder. Method: Mean thyroid-stimulating hormone (TSH) and outcome data were pooled from two 18-month, double-blind, placebo-controlled, maintenance studies of lamotrigine and lithium monotherapy. A post hoc analysis of 109 subjects (n = 55 lamotrigine, n = 32 lithium, n = 22 placebo) with serum TSH values at screening and either week 52 (±14 days) or study drop-out was conducted. Results: Lithium-treated subjects who required an intervention for a depressive episode had a significantly higher adjusted mean TSH level (4.4 μIU/ml) compared with lithium-treated subjects who did not require intervention for a depressive episode (2.4 μIU/ml). Conclusion: Lithium-related changes in thyroid function are clinically relevant and should be carefully monitored in the maintenance phase of bipolar disorder to maximize mood stability and minimize the risk of subsyndromal or syndromal depressive relapse.",
keywords = "Bipolar, Depression, Lithium, Thyroid-stimulating hormone",
author = "Frye, {Mark A} and L. Yatham and Ketter, {T. A.} and J. Goldberg and T. Suppes and Calabrese, {J. R.} and Bowden, {C. L.} and E. Bourne and Bahn, {R. S.} and B. Adams",
year = "2009",
month = "7",
doi = "10.1111/j.1600-0447.2008.01343.x",
language = "English (US)",
volume = "120",
pages = "10--13",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone

T2 - Results from two placebo-controlled bipolar i maintenance studies

AU - Frye, Mark A

AU - Yatham, L.

AU - Ketter, T. A.

AU - Goldberg, J.

AU - Suppes, T.

AU - Calabrese, J. R.

AU - Bowden, C. L.

AU - Bourne, E.

AU - Bahn, R. S.

AU - Adams, B.

PY - 2009/7

Y1 - 2009/7

N2 - Objective: To assess the relationship between depressive relapse and change in thyroid function in an exploratory post hoc analysis from a controlled maintenance evaluation of bipolar I disorder. Method: Mean thyroid-stimulating hormone (TSH) and outcome data were pooled from two 18-month, double-blind, placebo-controlled, maintenance studies of lamotrigine and lithium monotherapy. A post hoc analysis of 109 subjects (n = 55 lamotrigine, n = 32 lithium, n = 22 placebo) with serum TSH values at screening and either week 52 (±14 days) or study drop-out was conducted. Results: Lithium-treated subjects who required an intervention for a depressive episode had a significantly higher adjusted mean TSH level (4.4 μIU/ml) compared with lithium-treated subjects who did not require intervention for a depressive episode (2.4 μIU/ml). Conclusion: Lithium-related changes in thyroid function are clinically relevant and should be carefully monitored in the maintenance phase of bipolar disorder to maximize mood stability and minimize the risk of subsyndromal or syndromal depressive relapse.

AB - Objective: To assess the relationship between depressive relapse and change in thyroid function in an exploratory post hoc analysis from a controlled maintenance evaluation of bipolar I disorder. Method: Mean thyroid-stimulating hormone (TSH) and outcome data were pooled from two 18-month, double-blind, placebo-controlled, maintenance studies of lamotrigine and lithium monotherapy. A post hoc analysis of 109 subjects (n = 55 lamotrigine, n = 32 lithium, n = 22 placebo) with serum TSH values at screening and either week 52 (±14 days) or study drop-out was conducted. Results: Lithium-treated subjects who required an intervention for a depressive episode had a significantly higher adjusted mean TSH level (4.4 μIU/ml) compared with lithium-treated subjects who did not require intervention for a depressive episode (2.4 μIU/ml). Conclusion: Lithium-related changes in thyroid function are clinically relevant and should be carefully monitored in the maintenance phase of bipolar disorder to maximize mood stability and minimize the risk of subsyndromal or syndromal depressive relapse.

KW - Bipolar

KW - Depression

KW - Lithium

KW - Thyroid-stimulating hormone

UR - http://www.scopus.com/inward/record.url?scp=66749122990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66749122990&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0447.2008.01343.x

DO - 10.1111/j.1600-0447.2008.01343.x

M3 - Article

VL - 120

SP - 10

EP - 13

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

SN - 0001-690X

IS - 1

ER -